ClinicalTrials.gg
Not yet recruitingNCT07159893Updated Sep 8, 2025

Inectolizumab With Steroid Optimization in Newly Treated NMOSD

An interventional study of Inebilizumab + Rapid Steroid Tapering group and Inebilizumab + Standard Steroid Tapering group in Neuromyelitis Optica, Autoimmune Diseases and Demyelinating Autoimmune Diseases, CNS, sponsored by First Affiliated Hospital of Wenzhou Medical University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by First Affiliated Hospital of Wenzhou Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Title: Study of Inectolizumab Combined With Steroid Hormone Adjustment Strategies in Treatment-naive Patients With Neuromyelitis Optica Spectrum Disease Objective:This study aims to evaluate the steroid-sparing effect and safety of inebilizumab in treatment-naïve AQP4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) patients, while assessing its impact on EDSS score improvement during acute-phase treatment. The study will further explore treatment-related biomarkers, including dynamic changes in: immunoglobulin levels, lymphocyte subset profiles, serum AQP4-IgG titers, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NFL) levels.

Study Design:This is a single-center, randomized, open-label, prospective clinical study planning to enroll 25 treatment-naïve, anti-aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD) patients.

Read the detailed description

Research Objectives:

  • To investigate the steroid-sparing effect and safety of inebilizumab in treatment-naïve AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) patients.
  • To evaluate the efficacy of early inebilizumab initiation during acute attacks in improving EDSS scores and its safety profile in treatment-naïve AQP4-IgG+ NMOSD patients.

Research Background: Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing autoimmune disease characterized by inflammatory demyelination of the central nervous system, predominantly affecting young to middle-aged women and typically manifesting as optic neuritis and longitudinally extensive transverse myelitis, often causing irreversible neurological damage and significant disability. The pathogenesis centers on AQP4-IgG-mediated immune attacks through complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity, leading to astrocyte damage and neuroinflammation, with B cells and IL-6 playing key roles in disease progression. While traditional therapies (corticosteroids and immunosuppressants) have limited efficacy and significant side effects, newly approved biologics (inebilizumab, eculizumab, satralizumab) targeting B cells, complement, or IL-6 pathways have shown promising results in reducing relapses. Our preliminary data suggest early inebilizumab initiation during acute attacks (within 7-10 days) may improve neurological function (EDSS scores) while enabling rapid steroid tapering without increasing relapse risk. This study aims to systematically evaluate the feasibility and safety of accelerated steroid reduction during inebilizumab therapy in treatment-naïve AQP4-IgG+ NMOSD patients, while assessing the efficacy of early biologic intervention, with the goal of optimizing treatment strategies, improving patient outcomes, and informing future clinical guidelines.

Research Design: This prospective, randomized controlled trial will evaluate the steroid-sparing efficacy and safety profile of inebilizumab in treatment-naïve AQP4-IgG+ neuromyelitis optica spectrum disorder (NMOSD) patients. The study specifically aims to: (1) quantify inebilizumab's glucocorticoid dose-reduction potential, (2) assess its safety in acute-phase administration (initiated within 7-10 days of disease onset), and (3) measure treatment impact on disability outcomes (EDSS improvement). By systematically investigating whether early biologic intervention facilitates both rapid steroid tapering and neurological recovery, this research will generate critical evidence to optimize precision therapy for NMOSD patients.

Treatment Protocol:

Eligible NMOSD patients (n=25) will be randomized into two groups:

  • Experimental Group(n=12): Inebilizumab on Day 1 and Day 15. Oral steroids (60 mg qod)after second dose, halved every 2 weeks, stopped at Week 12.
  • Active comparator(n=13): Inebilizumab on Day 1 and Day 15. Oral steroids (60 mg qod) after second dose, halved every 4 weeks, stopped at Week 24.

Initial Treatment (Both Groups):

Days 1-5 (D1-D5): Methylprednisolone 1.0g IV daily (first infusion day designated as D1);Day 6 (D6): Switch to oral prednisone 60mg daily for 14 days + initiate first inebilizumab 300mg IV infusion ;Day 20 (D20): Second inebilizumab 300mg IV (15 days after first dose);Week 24: Third inebilizumab 300mg IV

Steroid Tapering Schedules:

- Rapid-Taper Group: D20: Prednisone reduced to 60mg every other day (EOD) D34 (after 2 weeks): Reduce to 30mg EOD D48 (after 2 weeks): Reduce to 15mg EOD D62 (after 2 weeks): Reduce to 10mg EOD D76 (after 2 weeks): Reduce to 5mg EOD D90 (Week 12): Discontinue steroids

- Standard-Taper Group: D20-D34: Continue prednisone 60mg daily for 4 weeks D34: Reduce to 60mg EOD D62 (after 4 weeks): Reduce to 30mg EOD D90 (after 4 weeks): Reduce to 15mg EOD D118 (after 4 weeks): Reduce to 10mg EOD D146 (after 4 weeks): Reduce to 5mg EOD D174 (Week 24): Discontinue steroids

Study Visits and Assessments:

  • Five scheduled visit timepoints Baseline (Visit 1, Week 0): First inebilizumab administration Visit 2 (Week 2) Visit 3 (Week 4) Visit 4 (Week 12) Visit 5 (Week 24)
  • Visit Procedures Visit 1:Laboratory tests (CBC, biochemistry, IgA/IgM/IgG levels, lymphocyte subsets)、MRI (brain/orbital/spinal)、Serum markers (AQP4-IgG, NFL, GFAP)、Clinical assessments (EDSS, Hauser Ambulation Index) Visit 2:Adverse event assessment Laboratory tests (CBC, biochemistry, IgA/IgM/IgG, lymphocyte subsets)、Clinical assessments Visit 3:Adverse event assessment、Clinical assessments Visit 4:Adverse event assessment Laboratory tests (CBC, biochemistry, IgA/IgM/IgG, lymphocyte subsets, serum markers)、Clinical assessments Visit 5:Full repeat of Visit 1 assessments
02

Conditions studied

  • Neuromyelitis Optica
  • Autoimmune Diseases
  • Demyelinating Autoimmune Diseases, CNS
03

In context

Neuromyelitis Optica

178 studies on the registry are indexed under Neuromyelitis Optica; 78 are open to participants now.

This study's planned enrollment of 25 is below the median of 29 across 108 interventional studies indexed under Neuromyelitis Optica.

Browse Neuromyelitis Optica studies →

Lead sponsor

First Affiliated Hospital of Wenzhou Medical University is the lead sponsor of 83 studies on the registry; 57 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who meet the 2015 International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorder (NMOSD) and are AQP4-IgG positive, with a first-attack episode;
  • Male or female,age >=18 and \<=65 years old;
  • EDSS score ≤ 7.5;
  • Female subjects of must have a negative pregnancy test result during the screening period and must use effective throughout the study period;
  • Voluntarily sign the form.

Exclusion criteria

Exclusion Criteria:

  • Laboratory abnormalities include: (white blood cell count \< 3×10⁹/L), (neutrophils \< 1.5×10⁹/L), ( \< 85 g/L), ( count \< 80×10⁹/L), (serum creatinine > 1.5×), (total > 1.5×ULN), ( (GOT) > 3×ULN), (ALT (GPT) > 3×ULN), (alkaline phosphatase > 2×ULN).
  • Patients currently suffering from active hepatitis or with a history of severe liver disease are ineligible. Based on the following serological test results for , anti-HBc antibodies, and anti-HBs antibodies, there is evidence of hepatitis B virus (HBV) infection: Patients with positive HBsAg should be excluded. For patients with negative HBsAg but positive anti-HBc antibodies, regardless of whether anti-HBs antibodies are positive or negative, HBV-DNA testing is required to determine their status: If HBV-DNA is positive, the patient should be excluded; if HBV-DNA is negative, the patient may be eligible for the trial.
  • Patients with other chronic active immune system diseases, or those with stable conditions but requiring therapy, are excluded, except for neuromyelitis optica spectrum disorder (NMOSD). Examples include rheumatoid arthritis, scleroderma, Sjögren's syndrome, ulcerative colitis, AIDS, genetic immunodeficiency, or drug-induced immunodeficiency. Patients with only positive autoantibodies but without clinical manifestations may be eligible for the trial.
  • Pregnant women, breastfeeding women, and patients who plan to conceive during the trial period.
  • Allergic reactions: Patients with a history of allergies to contrast agents administered via the parenteral route or to human-derived biological products.
  • Patients who received a , except for the herpes zoster vaccine, within 28 days prior to randomization.
  • Patients who have used rituximab or other monoclonal antibodies within 6 months prior to randomization
  • Patients who have received intravenous immunoglobulin (IVIG) within 28 days prior to randomization.
  • Patients who have undergone hematopoietic stem cell transplantation or lymphocyte irradiation before randomization.
  • Patients who have used agents such as azathioprine (Azathioprine, AZA, half-life t1/2 = 6 hrs), mycophenolate mofetil (Mycophenolate Mofetil, t1/2 = 16 hrs), leflunomide (Leflunomide, LEF, t1/2 = 14.7 hrs), tacrolimus (Tacrolimus, t1/2 = 43 hrs), teriflunomide (Teriflunomide, t1/2 = 18 days), cyclosporine (Cyclosporin, CsA, t1/2 = 27 hrs), methotrexate (Methotrexate, MTX, t1/2 = 14 hrs), mitoxantrone (Mitoxantrone, NVT, t1/2 = 37 hrs), and cyclophosphamide (Cyclophosphamide, CTX, t1/2 = 6 hrs) before randomization are excluded. Except for leflunomide and teriflunomide, patients can be enrolled if the exceeds five half-lives. For leflunomide and teriflunomide, patients need to undergo cholestyramine washout as follows: take 8 grams of cholestyramine orally three times daily for 11 days. If the 8-gram dose is not tolerated, it can be changed to 4 grams per dose, with the same frequency and duration.
  • Patients who have received any drug within 28 days or five half-lives of the trial drug (whichever is shorter) before randomization.
  • Patients with symptoms of severe mental illness who are clinically unable to co-operate;
  • Patients with malignant tumours.
  • Patients who have experienced any of the following events within 12 weeks prior to randomization: myocardial infarction, unstable ischemic heart disease, stroke, or (NYHA) Class IV heart failure.
  • Patients with herpes zoster infection, positive for antibodies, or positive for antibodies during the screening period.
  • Patients who are unable to undergo magnetic resonance imaging (MRI) during the trial period.
  • Patients whom the investigator deems unsuitable for participation in the trial.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Inebilizumab with Rapid Steroid Tapering group

    Participants receive: 1. Acute-phase: Methylprednisolone 1.0g IV daily (Days 1-5) 2. Maintenance-phase: * Day 6: Prednisone 60mg po daily + Inebilizumab 300mg IV * Day 20: Second inebilizumab 300mg IV + Prednisone reduced to 60mg po every other day 3. Steroid tapering schedule:Day 34→30mg EOD → Day 48→15mg EOD → Day 62→10mg EOD → Day 76→5mg EOD → Day 90→Discontinue 4. Long-term: Third inebilizumab 300mg IV at Week 24

    Drug: Inebilizumab + Rapid Steroid Tapering group

  • Active comparator
    Inebilizumab with Standard Steroid Tapering group

    Participants receive: 1. Acute-phase (Days 1-5):Methylprednisolone 1.0g IV daily 2. Maintenance-phase: * Day 6: Prednisone 60mg po daily +First inebilizumab 300mg IV * Day 20: Second inebilizumab 300mg IV+Continue prednisone 60mg po daily until Day 34 3. Steroid Tapering Schedule: Day 34→60mg EOD → Day 62→30mg EOD → Day 90→15mg EOD → Day 118→10mg EOD → Day 146→5mg EOD → Day 174→Discontinue 4. Long-term: Third inebilizumab 300mg IV at Week 24

    Drug: Inebilizumab + Standard Steroid Tapering group

Interventions

  • DrugInebilizumab + Rapid Steroid Tapering group

    Drug 1: Inebilizumab Generic Name: Inebilizumab Formulation: Injection (Intravenous) Dose: 300 mg Frequency:Day 6 (Week 0): First dose ;Day 20 (Week 2): Second dose ;Week 24: Third dose Route: Intravenous infusion Drug 2: Prednisone Generic Name: Prednisone Formulation: Tablet (Oral) Dose \& Tapering:Day 6-19: 60 mg daily;Day 20: 60 mg every other day (EOD) ;Day 34: 30 mg EOD → Day 48: 15 mg EOD → Day 62: 10 mg EOD → Day 76: 5 mg EOD → Day 90: Discontinue Route: Oral

    Also known as: Inebilizumab with rapid glucocorticoid taper group

  • DrugInebilizumab + Standard Steroid Tapering group

    Drug 1: Inebilizumab Generic Name: Inebilizumab Formulation: Injection (Intravenous) Dose: 300 mg Frequency:Day 6 (Week 0): First dose ;Day 20 (Week 2): Second dose ;Week 24: Third dose Route: Intravenous infusion Drug 2: Prednisone Generic Name: Prednisone Formulation: Tablet (Oral) Dose \& Tapering:Day 6-34: 60 mg daily;Day 34: 60 mg EOD → Day 62: 30 mg EOD → Day 90: 15 mg EOD → Day 118: 10 mg EOD → Day 146: 5 mg EOD → Day 174:Discontinue; Route: Oral

    Also known as: Inebilizumab with standard glucocorticoid taper group

06

What researchers measure

Primary outcomes

  1. The change in the average daily dose of corticosteroids between the two groups during the follow-up period compared to randomization (i.e., baseline

    Record the corticosteroid dose for patients at randomization (baseline) and during the follow-up period

    Time frame: Baseline, Week 2, Week 4, Week 12, Week 24

  2. Time to first clinical relapse

    Accurately document the time of symptom onset in patients.

    Time frame: From the date of randomization (baseline) to the date of first documented clinical relapse (as defined by protocol criteria), assessed up to 24 weeks.

Secondary outcomes

  1. The change in EDSS (Expanded Disability Status Scale) score from.

    Before patients enter the study (i.e., at randomization) and at each follow-up time point during the study period, the disability status of patients is assessed by a trained neurologist or study nurse, and the EDSS scores at baseline and follow-up time points are recorded.

    Time frame: Baseline,Week 2, Week 4, Week 12, Week 24

  2. The incidence, severity, and outcomes of adverse events in each group of patients

    Record the occurrence, severity, and outcomes of adverse events in patients at baseline and follow-up time points.

    Time frame: Baseline, Week 2, Week 4, Week 12, Week 24

  3. Area Under the Dose-Time Curve of Corticosteroids (AUDTC)

    Record the corticosteroid dose for patients at Week 24. Calculate the total area under the dose-time curve (AUDTC) by dividing the dose-time curve into multiple trapezoids, calculating the area of each trapezoid, and then summing these areas.

    Time frame: Week 24

  4. The change in the Hauser Walking Index from baseline for each group of patients.

    At baseline and follow-up time points, patients are required to walk 25 feet (approximately 8 meters) on a flat surface, and the time taken is recorded. The score is then determined according to the time taken to walk this distance and whether any assistive devices are used, in accordance with the scoring criteria.

    Time frame: Baseline, Week 2, Week 4, Week 12, Week 24

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for May 2026, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2025
First posted
Sep 8, 2025
StartEst.
Sep 2025
Primary completionEst.
May 2026
CompletionEst.
Sep 2026
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07159893
Lead sponsor
First Affiliated Hospital of Wenzhou Medical University
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Sep 2025 (estimated)
Primary completion
May 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Sep 8, 2025

Study contacts

Xu Zhang, Bachelor
Contact
drzhangxu@live.cn
0086-13587688130
Xu Zhang, Bachelor
principal investigator · First Affiliated Hospital of Wenzhou Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion